Valuation : IDEAYA Biosciences, Inc.

Market Cap 3.88B 3.33B 3.13B 2.86B 5.34B 366B 5.39B 37.02B 14.42B 187B 14.56B 14.24B 603B P/E 2026 *
-8.7x
P/E 2027 * -9.55x
Enterprise Value 2.88B 2.48B 2.33B 2.13B 3.98B 273B 4.01B 27.55B 10.73B 139B 10.83B 10.6B 449B EV / Sales 2026 *
73.3x
EV / Sales 2027 * 24.3x
Free-Float
97.81%
Yield 2026 *
-
Yield 2027 * -
08-31 IDEAYA Biosciences Announces Successful FDA Type C Meeting For IDE849 DLL3 TOP1 ADC On Phase 3 Registrational Trial Design For Potential Accelerated And Full Approval In Extensive Stage Small Cell Lung Cancer CI
08-31 IDEAYA Biosciences Plans Phase 3 Trial for Lung Cancer Therapy MT
08-19 Ideaya Biosciences, Genentech Partner for Pancreatic Cancer Trial MT
08-19 IDEAYA Biosciences, Inc. Enters Clinical Collaboration With Genentech To Evaluate IDE892 In Combination With RG6620 In MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer CI
08-07 Certain Pre-Funded Warrants of IDEAYA Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2026. CI
08-07 Certain Common Stock of IDEAYA Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2026. CI
08-07 Certain Stock Options of IDEAYA Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2026. CI
08-04 Wedbush Adjusts Price Target on IDEAYA Biosciences to $60 From $58, Maintains Outperform Rating MT
08-04 IDEAYA Biosciences Q2 Loss Widens From Q1, Revenue Rises MT
08-04 IDEAYA Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-04 Earnings Flash (IDYA) IDEAYA Biosciences Posts Q2 Net Loss $1.22 a Share, vs. FactSet Est of $1.18 Loss MT
08-04 Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q2 Revenue $8.9M, vs. FactSet Est of $8.0M MT
07-27 IDEAYA Biosciences Initiates Part 2 Monotherapy Expansion In Phase 1/2 Study Evaluating IDE892 In MTAP-Deleted Pancreatic And Lung Cancers CI
1 day+0.14%
1 week-3.97%
Current month+0.02%
1 month+13.31%
3 months+41.23%
6 months+16.90%
Current year+16.03%
1 week 38.9
Extreme 38.9
41.64
1 month 35.21
Extreme 35.21
42.68
Current year 26.81
Extreme 26.81
42.68
1 year 23.23
Extreme 23.23
42.68
3 years 13.45
Extreme 13.45
47.74
5 years 8.14
Extreme 8.14
47.74
10 years 2.95
Extreme 2.95
47.74
Manager TitleAgeSince
Chief Executive Officer 51 2015-05-31
Director of Finance/CFO 51 2025-04-30
Chief Tech/Sci/R&D Officer 59 2022-11-20
Director TitleAgeSince
Chairman 51 2026-06-16
Chairman 67 -
Director/Board Member 71 2015-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
7/7/26 Exercice

Controller/Auditor

28,650 0.0327%
6/16/26 Free

Director

20,000 0.0228%
3/2/26 Buy

Director

50,000 0.0570%
Change 5-day change 1-year change 3-year change Capi.($)
+0.07%-3.97%+55.71%+39.22% 3.88B
-0.24%-1.09%+2.00%+17.50% 50.14B
+1.34%-4.23%+432.55%+528.66% 44.85B
+0.90%+1.15%+43.76%+20.15% 43.43B
+0.09%-2.72%+7.76%+76.89% 41.14B
+0.43%-3.26%+14.75%+49.08% 32.92B
+0.34%+7.25% - - 17.56B
-0.48%-3.63%+22.47%+122.31% 16.55B
+0.93%+0.63%+16.86%+29.29% 14.65B
-0.67%-2.37%+78.26%+41.65% 13.93B
Average +0.23%-1.03%+74.90%+102.75% 27.9B
Weighted average by Cap. +0.33%-1.16%+92.28%+127.83%

Financials

2026 *2027 *
Net sales 39.36M 33.86M 31.78M 29.07M 54.26M 3.72B 54.69M 376M 146M 1.9B 148M 145M 6.12B 115M 99.37M 93.25M 85.32M 159M 10.92B 160M 1.1B 430M 5.58B 434M 424M 17.97B
Net income -432M -372M -349M -319M -596M -40.84B -600M -4.13B -1.61B -20.87B -1.62B -1.59B -67.22B -421M -362M -340M -311M -581M -39.81B -585M -4.02B -1.57B -20.35B -1.58B -1.55B -65.53B
Net Debt -991M -853M -800M -732M -1.37B -93.7B -1.38B -9.47B -3.69B -47.88B -3.72B -3.64B -154B -1.07B -918M -862M -788M -1.47B -101B -1.48B -10.19B -3.97B -51.56B -4.01B -3.92B -166B
Logo IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.
Employees
145
Date Price Change Volume
26-09-03 US$40.11 -0.15% 199,336
26-09-02 US$40.17 +0.55% 765,285
26-09-01 US$39.95 -0.37% 587,802
26-08-31 US$40.10 -0.02% 977,808
26-08-28 US$40.11 -3.97% 714,065
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
40.17USD
Average target price
52.15USD
Spread / Average Target
+29.83%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IDYA Stock